No immediate trading implications. Traders should monitor future Form 4 filings for any actual insider buying or selling activity, which could signal sentiment. The option grant is standard for executive compensation and not unusual for a biotech firm.
Price Chart
Executive Summary
Martin Mackay, Ph.D., a reporting person at Kailera Therapeutics, Inc., filed a Form 3 disclosing an initial grant of stock options and executed a Power of Attorney appointing three individuals to file SEC reports on his behalf. The filing is routine and relates to standard regulatory compliance for insider holdings.
Key Facts
- Martin Mackay filed a Form 3, indicating initial beneficial ownership of securities in Kailera Therapeutics, Inc.
- The filing discloses a stock option grant to purchase 170,194 shares, exercisable at $11.56 per share, with a 10-year term expiring March 10, 2036.
- Options vest 25% on March 10, 2027, and the remainder in 36 equal monthly installments thereafter, subject to continued service.
- A Power of Attorney was executed on February 27, 2026, authorizing Scott Akamine, John Mei, and Corey Manchester to file SEC reports (Forms 3, 4, 5, 144, 13D/G) on Mackay's behalf.
Financial Impact
Undisclosed value of stock option grant; no immediate financial impact to company or shareholder equity.
Risk Factors
- Potential for future dilution if options are exercised.
- Lack of transparency in exact fair value of the option grant, which is not disclosed in the filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-159669 |
| Document: 0001193125-26-159669-index-headers.html | 0001193125-26-159669 |
| Document: 0001193125-26-159669-index.html | 0001193125-26-159669 |
| Document: 0001193125-26-159669.txt | 0001193125-26-159669 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access